2024-519770-38-00RecruitingPhase 4
Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study).
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Jun 2026
Brief summary (registry, in English)
- Temporal Evolution of Biochemical Marker Levels in Blood During NTG-Induced Migraine Attacks and After Treatment with Sumatriptan and Rimegepant - Correlation of Biochemical Marker Profiles with Acute Treatment Response to Sumatriptan and Rimegepant During NTG-Induced Migraine Attacks.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 21 Jan 2025
- Start date
- 5 Mar 2026
- Lead sponsor
- Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
- Diseases
- Migraine
- EU CT number
- 2024-519770-38-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with episodic migraine who have fewer than 10 headache days a month and do not take preventive migraine treatment.
- Age
- Adults between 18 and 60 years old (the registry also lists 18 to 64 years).
- Sex
- All sexes can join.
- Disease stage
- Migraine with or without aura, diagnosed by the International Classification of Headache Disorders 3rd edition, with fewer than 10 headache days per month.
- Earlier treatment
- People cannot have taken preventive migraine treatment or drugs acting on the central nervous system. People with poor tolerance of triptans or gepants cannot join.
Main reasons for not taking part
- Cannot take nitroglycerin
- Pregnant women, or women who can have children and do not use an acceptable birth control method
- Past severe or refractory migraine attacks that did not respond to triptans, gepants or NSAIDs
- Unstable ischemic heart disease, cerebrovascular disease or peripheral vascular disease
- Significant liver disease or other relevant medical or psychiatric disease
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of poor tolerance or prior hypersensitivity reaction to triptans or gepants
- History of severe or refractory migraine attacks unresponsive to treatment with triptans, gepants, or NSAIDs
- Preventive treatment for migraines (includes antidepressants, beta-blockers, lisinopril or candesartan, topiramate, valproic acid, botulinum toxin, or CGRP-targeted therapies).
- Tretament with drugs acting on the central nervous system
Other illness
- Relevant medical or psychiatric diseases
- History of unstable ischemic heart disease, cerebrovascular disease, peripheral vasculopathy
- History of significant hepatic disease
Other
- Contraindication to nitroglycerin
- Child-bearing women that not use one acceptable method of birth contro
- Pregnant women
Who the study is looking for
- Adults between 18 and 60 years old.
- Diagnosis of migraine, with or without aura, according to the The International Classification of Headache Disorders 3rd edition.
- According to the calendar, frequency of cefalea < 10 days/month.
- Signature of the Inform Consent Form.
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.